Gilead

Gilead Sciences stock upgraded by Raymond James on strong growth outlook for new drugs By…

On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered…

Compugen signs cancer drug licensing deal with Gilead Sciences

Investor Empires

US biopharmaceutical giant Gilead Sciences Inc. (Nasdaq: GILD) today announced an agreement with Israeli clinical-stage cancer immunotherapy company Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), which uses computational…

Eli Lilly, Gilead favorites at BofA ahead of Q3 earnings

Investor Empires

Fokusiert Heading into the biopharma Q3 earnings season, Bank of America has taken a bullish stance on Eli Lilly (NYSE:LLY) and Gilead (NASDAQ:GILD) while raising concerns on COVID-era favorites such as Pfizer (NYSE:PFE) and Regeneron…